The economic ramifications of hepatitis C (HCV) are staggering. Estimates suggest the disease could impose a $1.17 trillion burden on China from 2023 to 2050. This is the crux of the hepatitis C investment impact article we cover below, meeting WHO’s 2030 HCV diagnosis and treatment targets requires $69.72 billion. This investment could avert over 1 million HCV-related deaths while yielding substantial health and economic benefits—including increased GDP growth and cost-effectiveness.

Accelerating Health Gains Through Timely Investment

Accelerating investment to meet WHO targets by 2030—rather than 2040 or 2050—leads to earlier and more significant cost savings. This approach reduces long-term disease management expenditures and provides greater productivity gains. The macroeconomic burden of untreated HCV could reach $1.17 trillion between 2023 and 2050. Rapidly scaling up resources to meet WHO’s 2030 targets could prevent 0.66 million hepatocellular carcinoma cases and 1.10 million HCV-related deaths. This would generate $68.33 billion in societal economic productivity gains. Early investments yield substantial returns, with healthcare savings starting by 2037 and societal savings by 2034. The GDP gain from early intervention could reach $0.56 trillion, outperforming later projections.

The Financial Justification for Screening and Treatment

Investments in universal HCV screening and treatment are highly cost-effective, especially when prioritizing high-risk populations. The incremental cost-effectiveness ratios (ICERs) fall well below China’s accepted thresholds, indicating a strong societal return on investment (ROI).

The WHO aims to eliminate hepatitis C by 2030, targeting an 80% reduction in incidence and a 65% drop in HCV-related mortality. Since 2019, China has made remarkable progress, including an 85% reduction in DAA prices, making treatment far more affordable. Yet, only 9% of HCV patients received treatment as of 2022.

Delays in elimination targets worsen health outcomes and increase long-term costs. Accelerating screening and treatment is imperative to maximize societal benefits, reinforcing the need to prioritize HCV elimination in national health agendas.

Recommendations

Accelerated HCV elimination is cost-effective for health systems and society, improving workforce productivity and reducing premature mortality. Policymakers can use these models for resource allocation purposes. DAA price reductions and insurance coverage make large-scale elimination feasible. Further price negotiations and reimbursement strategies will amplify economic returns. Expanded reimbursement for HCV diagnostics and treatment, despite short-term spending increases, highlights the need for innovative payment models to optimize costs.

In conclusion, the hepatitis C investment impact is profound. It presents a crucial opportunity for China to address a major health challenge while boosting its economy. Accelerated investments are essential for optimal health and societal outcomes, making a strong case for prioritizing HCV eradication. Aligning health policy, pricing, and market access strategies can turn HCV elimination into reality, benefiting China in the long-run.

For more insights, refer to the source here.